Biotechnology
Healthcare
Investing News
Market News
Technology
The Market Buzz
Otonomy Announces Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
Otonomy, Inc. (NASDAQ: OTIC) reported that the OTO-313 Phase 2 trial in tinnitus demonstrated no meaningful benefit versus placebo for primary and secondary endpoints across all timepoints. The phase...